Cargando…

Site-Specific Survival of Extra Nodal Diffuse Large B-Cell Lymphoma and Comparison With Gastrointestinal Diffuse Large B-Cell Lymphoma

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) constitutes 30% of all non-Hodgkin’s lymphomas. It can present as a nodal disease or as an extra nodal disease. Based on the site of origin, extra nodal DLBCL (EN-DLBCL) may have a distinct clinical outcome. Apart from the site of origin, factors inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Varsha, Singh, Vinit, Bajwa, Ravneet, Meghal, Trishala, Sen, Shuvendu, Greenberg, David, Anne, Madhurima, Levitt, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076143/
https://www.ncbi.nlm.nih.gov/pubmed/35573751
http://dx.doi.org/10.14740/jh984
_version_ 1784701848084545536
author Gupta, Varsha
Singh, Vinit
Bajwa, Ravneet
Meghal, Trishala
Sen, Shuvendu
Greenberg, David
Anne, Madhurima
Levitt, Michael J.
author_facet Gupta, Varsha
Singh, Vinit
Bajwa, Ravneet
Meghal, Trishala
Sen, Shuvendu
Greenberg, David
Anne, Madhurima
Levitt, Michael J.
author_sort Gupta, Varsha
collection PubMed
description BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) constitutes 30% of all non-Hodgkin’s lymphomas. It can present as a nodal disease or as an extra nodal disease. Based on the site of origin, extra nodal DLBCL (EN-DLBCL) may have a distinct clinical outcome. Apart from the site of origin, factors including demographics, stage, and presence of any other primary malignancy also affect the outcome. The purpose of our study was to characterize prognostically distinct groups based on the site of presentation of EN-DLBCL. METHODS: We used 18 registries in Surveillance, Epidemiology, and End Results database to identify the patients with EN-DLBCL for 2000 - 2015 with last follow-up till December 31, 2018. A total of 30,290 EN-DLBCL patients were selected and categorized based on 13 broad sites grouping. Demographic variables were summarized. We did overall survival analysis with univariate and multivariate Cox-proportional hazard modeling. Short-term survival trend was calculated as well. RESULTS: The percentage of EN-DLBCL of all DLBCLs is 34.48%. EN-DLBCL was comparatively seen more in males (54.94%) and non-Hispanic whites (71.52%). In terms of clinical characteristics, patients with EN-DLBCL were mostly diagnosed at age ≥ 60 years (66.11%), early stage (69.33%), and presentation as first primary cancer (81.89%). A higher risk of mortality was seen in non-Hispanic black (hazard ratio (HR) 1.36), with late age of onset (HR 2.69), late stage at presentation (HR 1.42), and with history of other malignancy (HR 1.29). Compared to the intestinal tract, the risk of overall mortality was higher in individuals with involvement of nervous system (HR 1.85), pancreas and hepatobiliary system (HR 1.22), and respiratory system (HR 1.18) and the best outcomes were seen in heart and mediastinal site (HR 0.58) of DLBCL. CONCLUSION: Based upon our population-based study, we conclude that primary site of presentation of EN-DLBCL is an important prognostic factor with significant difference in survival based on histological and epidemiological characteristics.
format Online
Article
Text
id pubmed-9076143
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-90761432022-05-12 Site-Specific Survival of Extra Nodal Diffuse Large B-Cell Lymphoma and Comparison With Gastrointestinal Diffuse Large B-Cell Lymphoma Gupta, Varsha Singh, Vinit Bajwa, Ravneet Meghal, Trishala Sen, Shuvendu Greenberg, David Anne, Madhurima Levitt, Michael J. J Hematol Original Article BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) constitutes 30% of all non-Hodgkin’s lymphomas. It can present as a nodal disease or as an extra nodal disease. Based on the site of origin, extra nodal DLBCL (EN-DLBCL) may have a distinct clinical outcome. Apart from the site of origin, factors including demographics, stage, and presence of any other primary malignancy also affect the outcome. The purpose of our study was to characterize prognostically distinct groups based on the site of presentation of EN-DLBCL. METHODS: We used 18 registries in Surveillance, Epidemiology, and End Results database to identify the patients with EN-DLBCL for 2000 - 2015 with last follow-up till December 31, 2018. A total of 30,290 EN-DLBCL patients were selected and categorized based on 13 broad sites grouping. Demographic variables were summarized. We did overall survival analysis with univariate and multivariate Cox-proportional hazard modeling. Short-term survival trend was calculated as well. RESULTS: The percentage of EN-DLBCL of all DLBCLs is 34.48%. EN-DLBCL was comparatively seen more in males (54.94%) and non-Hispanic whites (71.52%). In terms of clinical characteristics, patients with EN-DLBCL were mostly diagnosed at age ≥ 60 years (66.11%), early stage (69.33%), and presentation as first primary cancer (81.89%). A higher risk of mortality was seen in non-Hispanic black (hazard ratio (HR) 1.36), with late age of onset (HR 2.69), late stage at presentation (HR 1.42), and with history of other malignancy (HR 1.29). Compared to the intestinal tract, the risk of overall mortality was higher in individuals with involvement of nervous system (HR 1.85), pancreas and hepatobiliary system (HR 1.22), and respiratory system (HR 1.18) and the best outcomes were seen in heart and mediastinal site (HR 0.58) of DLBCL. CONCLUSION: Based upon our population-based study, we conclude that primary site of presentation of EN-DLBCL is an important prognostic factor with significant difference in survival based on histological and epidemiological characteristics. Elmer Press 2022-04 2022-04-22 /pmc/articles/PMC9076143/ /pubmed/35573751 http://dx.doi.org/10.14740/jh984 Text en Copyright 2022, Gupta et al. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Gupta, Varsha
Singh, Vinit
Bajwa, Ravneet
Meghal, Trishala
Sen, Shuvendu
Greenberg, David
Anne, Madhurima
Levitt, Michael J.
Site-Specific Survival of Extra Nodal Diffuse Large B-Cell Lymphoma and Comparison With Gastrointestinal Diffuse Large B-Cell Lymphoma
title Site-Specific Survival of Extra Nodal Diffuse Large B-Cell Lymphoma and Comparison With Gastrointestinal Diffuse Large B-Cell Lymphoma
title_full Site-Specific Survival of Extra Nodal Diffuse Large B-Cell Lymphoma and Comparison With Gastrointestinal Diffuse Large B-Cell Lymphoma
title_fullStr Site-Specific Survival of Extra Nodal Diffuse Large B-Cell Lymphoma and Comparison With Gastrointestinal Diffuse Large B-Cell Lymphoma
title_full_unstemmed Site-Specific Survival of Extra Nodal Diffuse Large B-Cell Lymphoma and Comparison With Gastrointestinal Diffuse Large B-Cell Lymphoma
title_short Site-Specific Survival of Extra Nodal Diffuse Large B-Cell Lymphoma and Comparison With Gastrointestinal Diffuse Large B-Cell Lymphoma
title_sort site-specific survival of extra nodal diffuse large b-cell lymphoma and comparison with gastrointestinal diffuse large b-cell lymphoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076143/
https://www.ncbi.nlm.nih.gov/pubmed/35573751
http://dx.doi.org/10.14740/jh984
work_keys_str_mv AT guptavarsha sitespecificsurvivalofextranodaldiffuselargebcelllymphomaandcomparisonwithgastrointestinaldiffuselargebcelllymphoma
AT singhvinit sitespecificsurvivalofextranodaldiffuselargebcelllymphomaandcomparisonwithgastrointestinaldiffuselargebcelllymphoma
AT bajwaravneet sitespecificsurvivalofextranodaldiffuselargebcelllymphomaandcomparisonwithgastrointestinaldiffuselargebcelllymphoma
AT meghaltrishala sitespecificsurvivalofextranodaldiffuselargebcelllymphomaandcomparisonwithgastrointestinaldiffuselargebcelllymphoma
AT senshuvendu sitespecificsurvivalofextranodaldiffuselargebcelllymphomaandcomparisonwithgastrointestinaldiffuselargebcelllymphoma
AT greenbergdavid sitespecificsurvivalofextranodaldiffuselargebcelllymphomaandcomparisonwithgastrointestinaldiffuselargebcelllymphoma
AT annemadhurima sitespecificsurvivalofextranodaldiffuselargebcelllymphomaandcomparisonwithgastrointestinaldiffuselargebcelllymphoma
AT levittmichaelj sitespecificsurvivalofextranodaldiffuselargebcelllymphomaandcomparisonwithgastrointestinaldiffuselargebcelllymphoma